Physician profile
Raminder P Mand
NPI 1609032358
$5,774.92
in general payments reported to CMS, 2019-2025
23 companies · $649 in 2025
The $649 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $399 · 2021: $1,104 · 2022: $1,349 · 2023: $960 · 2024: $831 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,419 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,419.12 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,149.82 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $711.25 | 2019-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $679.74 | 2019-2025 | Veltassa |
| Amgen INC. | $522.39 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $496.66 | 2022-2025 | |
| Horizon Therapeutics Plc | $412.22 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $352.25 | 2021-2025 | Shingrix |
| Otsuka America Pharmaceutical, INC. | $337.78 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $259.32 | 2019-2025 | Vafseo |
| Abbott Laboratories | $157.49 | 2021 | |
| Janssen Pharmaceuticals, INC | $93.94 | 2019-2022 | |
| Ardelyx, INC. | $82.55 | 2023-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $73.12 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $63.14 | 2021-2022 | |
| Lilly USA, LLC | $60.51 | 2020-2025 | Mounjaro, Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $59.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $54.85 | 2024 | |
| Novo Nordisk INC | $52.45 | 2023-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.75 | 2024 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $30.44 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.75 | 2023 | Jynarque |
| Exact Sciences Corporation | $25.32 | 2025 | The Cologuard Plus Collection Kit |
| Scpharmaceuticals INC. | $22.03 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raminder Mand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.